Bromocriptine acute effect on insulin, glucagon and growth hormone levels in acromegalic patients
Tóm tắt
Từ khóa
Tài liệu tham khảo
Corrodi H., Fuxe K., Hökfelt T., Lidbrink P., Ungerstedt U. Effect of ergot drugs on central catecholamine neurons: evidence for a stimulation of central dopamine neurons. J. Pharm. Pharmacol. 25: 409, 1973.
Liuzzi A., Chiodini P.G., Botalla L., Cremascoli G., Müller E.E., Silvestrini F. Decreased plasma growth hormone (GH) levels in acromegalics following CB-154 (2-Br-α-ergocryptine) administration. J. Clin. Endocrinol. Metab. 38: 910, 1974.
Camanni F., Massara F., Belforte L., Molinatti G.M. Changes in plasma growth hormone levels in normal and acromegalic subjects following administration of 2-Bromo-d-Ergocryptine. J. Clin. Endocrinol. Metab. 40: 363, 1975.
Thorner M.O., Chait A., Aitken M., Benker G., Bloom S.R., Mortimer C.H., Sanders P., Stuart Mason A., Besser G.M. Bromocriptine treatment of acromegaly. Br. Med. J. 1: 299, 1975.
Sachdev Y., Gomez-Pan A., Tunbridge W.M.G., Duns A., Weightman D.R., Hall R. Bromocriptine therapy in acromegaly. Lancet 2: 1164, 1975.
Belforte L., Camanni F., Chiodini P.G., Liuzzi A., Massara F., Molinatti G.M., Müller E.E., Silvestrini F. Long-term treatment with 2-Br-α-ergocryptine in acromegaly. Acta Endocrinol. (Kbh.) 85: 235, 1977.
Fossati P., Asfour M., Brion-Brevan B., Fourlinnie J.CI., Cappoen J.P., Dalle-Furnari M.A. Effet thérapeutiques de la bromocriptine chez 10 acromégales. Ann. Endocrinol. (Paris) 37: 299, 1976.
Halse J., Haugen H.N., Böhmer T. Bromocriptine treatment in acromegaly: clinical and biochemical effects. Acta Endocrinol. (Kbh.) 86: 464, 1977.
Faloona G.R., Unger R.H. Glucagon. In: Jaffe B.M., Behrmon H.R. (Eds.), Methods of hormone radioimmunoassay. Academic Press Inc. New York, 1974, p. 317.
Herbert U., Lau K.S., Gottlieb C.W., Bleicher S.J. Coated-charcoal immunoassay of insulin. J. Clin. Endocrinol. Metab. 25:1375, 1965.
Molinatti G.M., Massara F., Strumia E., Pennisi F., Scassellati G.A., Vancheri L. Radioimmunoassay of human growth hormone. J. Nucl. Biol. Med. All. Sci. 13: 26, 1969.
Cegrell L. The occurrence of biogenic monoamines in the mammalian endocrine pancreas. Acta Physiol. Scand. (Suppl.) 314:1, 1968.
Calne D.B., Karoum F., Ruthven C.R.J. The metabolism of orally administered L-dopa in parkinsonism. Br. J. Pharmacol. 37: 37, 1969.
Rayfield E.J., George D.T., Eichner H.L., Hsu H.T. L-dopa stimulation of glucagon secretion in man. N. Engl. J. Med. 18:589, 1975.
Lorenzi M., Tsalikian E., Bohannon N.V., Gerich J.E., Karan J.H., Forsham P.H. Differential sensitivity of pancreatic glucagon to L-dopa and apomorphine in man. Evidence against a direct dopaminergic mechanism of stimulation. Proceedings of the 5th International Congress of Endocrinology, Hamburg 1976, p. 341, (Abstract).
Thorner M.O., Wass J.A.H., Jones A., Bloom S.R., McLeod R.M. Effect of piribedil infusions on circulating GH, insulin, glucagon, Cortisol and blood sugar in man. Proceedings of the 5th International Congress of Endocrinology, Hamburg 1976, p. 24 (Abstract).